Q-omics provides the consensus-scored EIF5AP3 profile across patient tissues and cancer cell-line models. EIF5AP3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, EIF5AP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, EIF5AP3 RNA expression shows 8,786 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BLCA, KIRC, and LAML as cancer lineages where EIF5AP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF5AP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF5AP3 survival associations across molecular data types. EIF5AP3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF5AP3 RNA expression–survival associations across cancer types. High EIF5AP3 expression shows unfavorable associations in UCEC, MESO, UVM, SARC and ACC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for EIF5AP3 RNA expression.
This table summarizes EIF5AP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF5AP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF5AP3 shows higher tumor expression in KIRC, COAD, STAD, BRCA, HNSC and LIHC. The KIRC box plot shows higher EIF5AP3 RNA expression in tumor versus normal tissue (log2 FC = +0.300, t-test p < 0.001).
This table shows molecular features associated with EIF5AP3 in patient tissues and cancer cell lines. In patient samples, EIF5AP3 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
